A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
by on Tuesday, August 7th, 2012 | No Comments
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: GS-1101
Sponsors: Gilead Sciences; Gilead Sciences
Not yet recruiting – verified August 2012